Answers are grounded in this paper and cite their sources.
Background: Antibody-mediated rejection remains a major threat to long-term graft function after lung transplantation. Current therapies aim to eliminate circulating antibodies and suppress B-cell-activity but often fail to reduce donor-specific antibodies. Daratumumab, a monoclonal antibody targeting CD38, has shown potential in depleting antibody-producing plasma cells. This study investigates the clinical application of daratumumab in lung transplant recipients. Methods: We performed a retrospective single-center study including all lung transplant recipients treated with subcutaneous daratumumab for antibody-mediated rejection A total of 14 patients with newly developed donor-specific antibodies and clinical antibody-mediated rejection were analyzed. Results: In all patients with AMR, antibodies directed against human leukocyte antigen class I decreased to less than 25-50% of baseline levels within 12 weeks. Antibodies against class II also declined in 5 patients. Eleven patients survived the initial AMR episode. Chronic lung allograft dysfunction was already present in several patients before the AMR episode, while others developed CLAD during follow-up. The treatment was generally well tolerated with the most common side effects being leukopenia, hypogammaglobulinemia and infections. Conclusions: CD38-targeted therapy with daratumumab may represent a promising addition to the antibody mediated rejection treatment panel.
No takes yet. Share an insight, caveat, or question.
Maggioni et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: